{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:12:40Z","timestamp":1782385960422,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019042","name":"Jiangsu Ocean University","doi-asserted-by":"publisher","award":["202411641140Y"],"award-info":[{"award-number":["202411641140Y"]}],"id":[{"id":"10.13039\/501100019042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019042","name":"Jiangsu Ocean University","doi-asserted-by":"publisher","award":["202211641193H"],"award-info":[{"award-number":["202211641193H"]}],"id":[{"id":"10.13039\/501100019042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019042","name":"Jiangsu Ocean University","doi-asserted-by":"publisher","award":["SJCX24_2101"],"award-info":[{"award-number":["SJCX24_2101"]}],"id":[{"id":"10.13039\/501100019042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejpb.2026.114988","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:54:10Z","timestamp":1767891250000},"page":"114988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A new drug-drug co-amorphous system of imipramine and celecoxib with improved solubility and synergistic antinociceptive effects"],"prefix":"10.1016","volume":"220","author":[{"given":"Zhiling","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2826-4281","authenticated-orcid":false,"given":"Tao","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.114988_b0005","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2026.114988_b0010","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1097\/j.pain.0000000000001824","article-title":"Neuropathic pain in the community: prevalence, impact, and risk factors","volume":"161","author":"Smith","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.ejpb.2026.114988_b0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-pharmtox-010818-021524","article-title":"Neuropathic pain: mechanism-based therapeutics","volume":"60","author":"Bannister","year":"2020","journal-title":"Annu. Rev. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.114988_b0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.anclin.2022.04.002","article-title":"Multimodal Analgesia","volume":"40","author":"O'Neill","year":"2022","journal-title":"Anesthesiol. Clin."},{"key":"10.1016\/j.ejpb.2026.114988_b0025","article-title":"Novel drug-drug co-amorphous systems of olaparib with nonsteroidal anti-inflammatory drugs with improved solubility, physical stability, antitumor activity and pharmacokinetics","volume":"101","author":"Luo","year":"2024","journal-title":"J. Drug Deliv. Sci. Tec."},{"key":"10.1016\/j.ejpb.2026.114988_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124470","article-title":"Different or the same? exploring the physicochemical properties and molecular mobility of celecoxib amorphous forms","volume":"661","author":"Wang","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.114988_b0035","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1021\/acs.molpharmaceut.5c00278","article-title":"Molar ratio-dependent crystallization in coamorphous celecoxib\u2013carbamazepine systems: the interplay of thermodynamics and kinetics","volume":"22","author":"Luo","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.114988_b0040","doi-asserted-by":"crossref","unstructured":"A. O\u2019Sullivan, K.M. Ryan, L. Padrela, Amorphization versus cocrystallization of celecoxib-tramadol hydrochloride using CO2-assisted nano-spray drying, J. CO2 Util. 73 (2023) 102529, https:\/\/doi.org\/10.1016\/j.jcou.2023.102529.","DOI":"10.1016\/j.jcou.2023.102529"},{"key":"10.1016\/j.ejpb.2026.114988_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114333","article-title":"Nucleotides as new co-formers in co-amorphous systems: enhanced dissolution rate, water solubility and physical stability","volume":"200","author":"Liu","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.114988_b0050","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/1570159X19666210609161447","article-title":"Depression and pain: use of antidepressants","volume":"20","author":"Bonilla-Jaime","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejpb.2026.114988_b0055","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1093\/pm\/pnz075","article-title":"A comprehensive algorithm for management of neuropathic pain","volume":"20","author":"Bates","year":"2019","journal-title":"Pain Med."},{"key":"10.1016\/j.ejpb.2026.114988_b0060","unstructured":"R. Fayez, V. Gupta, Imipramine, StatPearls Publishing, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557656\/."},{"key":"10.1016\/j.ejpb.2026.114988_b0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00004714-200204000-00008","article-title":"Specific side effects of long-term imipramine management of panic disorder","volume":"22","author":"Mavissakalian","year":"2002","journal-title":"J. Clin. Psychopharm."},{"key":"10.1016\/j.ejpb.2026.114988_b0070","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2165\/00003495-200767160-00008","article-title":"Celecoxib: a review of its use in the management of arthritis and acute pain","volume":"67","author":"Frampton","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2026.114988_b0075","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3390\/pharmaceutics12111043","article-title":"Preparation and evaluation of amino acid conjugates of celecoxib as prodrugs to improve the pharmacokinetic and therapeutic properties of celecoxib","volume":"12","author":"Lee","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.114988_b0080","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/j.pain.0000000000001122","article-title":"Inflammation in the pathophysiology of neuropathic pain","volume":"159","author":"Sommer","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.ejpb.2026.114988_b0085","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/biomedicines10061413","article-title":"Synergistic antinociceptive effects of indomethacin-pregabalin and meloxicam-pregabalin in paclitaxel-induced neuropathic pain","volume":"10","author":"Ma","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejpb.2026.114988_b0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.biopha.2018.01.102","article-title":"Efficacy and safety of combined low doses of either diclofenac or celecoxib with gabapentin versus their single high dose in treatment of neuropathic pain in rats","volume":"100","author":"Ibrahim","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2026.114988_b0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/JCMA.0000000000000115","article-title":"Synergistic symptom-specific effects of ketorolac\u2013tramadol and ketorolac\u2013pregabalin in a rat model of peripheral neuropathy","volume":"82","author":"Lin","year":"2019","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.ejpb.2026.114988_b0100","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/mp049938f","article-title":"Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility","volume":"1","author":"Gupta","year":"2004","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.114988_b0105","doi-asserted-by":"crossref","first-page":"20523","DOI":"10.1039\/C7CP04124A","article-title":"The amorphous state: First-principles derivation of the Gordon-Taylor equation for direct prediction of the glass transition temperature of mixtures; estimation of the crossover temperature of fragile glass formers; physical basis of the \u201crule of 2\/3\u201d","volume":"19","author":"Skrdla","year":"2017","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ejpb.2026.114988_b0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/pharmaceutics14010023","article-title":"Two novel palbociclib-resorcinol and palbociclib-orcinol cocrystals with enhanced solubility and dissolution rate","volume":"14","author":"Duan","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.114988_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135101","article-title":"Synthesis and structural characterization of a novel palbociclib-kaempferol cocrystal with improved tabletability and synergistic antitumor activity","volume":"1281","author":"Zhou","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejpb.2026.114988_b0120","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1021\/acs.cgd.2c00370","article-title":"Two cocrystals of olaparib with flavonoids toward sustained release: structure, dissolution behavior, and anticancer activity analysis","volume":"22","author":"Duan","year":"2022","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2026.114988_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175870","article-title":"Pregabalin can interact synergistically with Kv7 channel openers to exert antinociception in mice","volume":"954","author":"Huang","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.114988_b0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pharmthera.2010.04.011","article-title":"The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations","volume":"127","author":"Tallarida","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.114988_b0135","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0304-3959(01)00267-6","article-title":"The analgesic effect of codeine as compared to imipramine in different human experimental pain models","volume":"92","author":"Enggaard","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.ejpb.2026.114988_b0140","doi-asserted-by":"crossref","unstructured":"L. Hearn, S. Derry, T. Phillips, et al., Imipramine for neuropathic pain in adults, Cochrane DB. Syst. Rev. 5 (2014) CD010769, https:\/\/doi.org\/10.1002\/14651858.CD010769.pub2.","DOI":"10.1002\/14651858.CD010769.pub2"},{"key":"10.1016\/j.ejpb.2026.114988_b0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10195-009-0077-z","article-title":"Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain","volume":"10","author":"Romano","year":"2009","journal-title":"J. Orthop. Traumatol."},{"key":"10.1016\/j.ejpb.2026.114988_b0150","article-title":"Preemptive analgesia in total knee arthroplasty: comparing the effects of single dose combining celecoxib with pregabalin and repetition dose combining celecoxib with pregabalin: double-blind controlled clinical trial","volume":"2018","author":"Lubis","year":"2018","journal-title":"Pain Res. Treat."},{"key":"10.1016\/j.ejpb.2026.114988_b0155","series-title":"In situ monitoring of pharmaceutical crystallization","author":"Aina","year":"2012"},{"key":"10.1016\/j.ejpb.2026.114988_b0160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejpb.2022.10.008","article-title":"Improving physicochemical properties and pharmacological activities of ternary co-amorphous systems","volume":"181","author":"Fang","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.114988_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103883","article-title":"Drug\u2013drug co-amorphous systems: an emerging formulation strategy for poorly water-soluble drugs","volume":"29","author":"Wang","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2026.114988_b0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2013.11.057","article-title":"Impact of surfactants on the crystal growth of amorphous celecoxib","volume":"461","author":"Mosquera-Giraldo","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.114988_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121475","article-title":"Design and molecular insights of drug-active metabolite based co-amorphous formulation: a case study of toltrazuril-ponazuril co-amorphous","volume":"615","author":"Li","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.114988_b0180","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1021\/mp200436q","article-title":"Enhancement of amorphous celecoxib stability by mixing it with octaacetylmaltose: the molecular dynamics study","volume":"9","author":"Grzybowska","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.114988_b0185","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijpharm.2016.08.034","article-title":"Enhanced oral delivery of celecoxib via the development of a supersaturable amorphous formulation utilising mesoporous silica and co-loaded HPMCAS","volume":"512","author":"Lain\u00e9","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.114988_b0190","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1021\/acs.cgd.5b00349","article-title":"Coamorphous lurasidone hydrochloride\u2013saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with pH-independent solubility behavior","volume":"15","author":"Qian","year":"2015","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2026.114988_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2017.08.123","article-title":"Supersaturating drug delivery systems: the potential of co-amorphous drug formulations","volume":"532","author":"Laitinen","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.114988_b0200","doi-asserted-by":"crossref","DOI":"10.1039\/C6RA18022A","article-title":"Charge-assisted intermolecular hydrogen bond formed in coamorphous system is important to relieve the pH-dependent solubility behavior of lurasidone hydrochloride","volume":"6","author":"Qian","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2026.114988_b0205","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jamaneurol.2016.0383","article-title":"The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling","volume":"73","author":"Kolb","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejpb.2026.114988_b0210","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrneurol.2014.211","article-title":"Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain","volume":"10","author":"Sisignano","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejpb.2026.114988_b0215","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspe."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:19:47Z","timestamp":1768990787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"alternative-id":["S0939641126000093"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.114988","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new drug-drug co-amorphous system of imipramine and celecoxib with improved solubility and synergistic antinociceptive effects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.114988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114988"}}